Molecular imaging is a promising approach for achieving precision medicine. It can provide important functional information for improved diagnosis, treatment planning, prognostic and predictive information and evaluation of treatment response for cancer patients. The purpose of this article is to review the current status of molecular imaging agents applicable to breast cancer.
Aunt Minnie (5/31, Yee) reports that "starting breast cancer screening at 50 means that up to 20% of breast cancers could be missed -- offering more proof that women between the ages of 40 and 49 should be screened regularly, according to a study published online May 15 in the American Journal of Roentgenology."
The Society of Breast Imaging and more than 300 organizations and institutions signed a letter to urge Congress to increase funding to the National Institutes of Health. The letter requests an additional $2 billion to the NIH in 2018.
The Radiology Business Journal (5/18, Pearson) reports that research suggests “lidocaine buffered with sodium bicarbonate is significantly more comfortable than plain lidocaine when administered for pain control to women undergoing ultrasound-guided core-needle breast biopsies.” Researchers also found that “the combination is...less painful than lidocaine alone for women experiencing preprocedural breast pain ahead of intradermal anesthesia injections as well as certain patients receiving anesthesia injections in parenchymal (function-essential) breast tissues.” The findings were published online in the Journal of the American College of Radiology.
Aunt Minnie (5/19, Yee) reports “a shortened protocol for breast MRI is just as effective in finding cancer as a full protocol, and it can cut the time a patient is in the magnet by almost 90%, according to a study published” in Academic Radiology. The researchers concluded that “abbreviated MRI protocols may provide opportunity to minimize time, costs, and patient discomfort.” The article points out that the American College of Radiology “has yet to weigh in on abbreviated sequences.”